By Colin Kellaher

Celgene Corp. (CELG) on Tuesday said the U.S. Food and Drug Administration granted priority review to its supplemental new-drug application for Revlimid in combination with rituximab in a form of the blood cancer lymphoma.

The Summit, N.J., biopharmaceutical company said the sNDA covers the treatment of patients with previously treated follicular and marginal zone lymphoma.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.

Celgene, which in January announced a deal to be acquired by Bristol-Myers Squibb Co. (BMY), said the FDA set a target action date of June 27.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

February 26, 2019 08:29 ET (13:29 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Celgene Charts.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Celgene Charts.